{"success":true,"data":{"pressRelease":{"id":"154734","rtpr_id":"nGNE6vl5ZB-20260929","ticker":"IBAB","exchange":"","all_tickers":["IBAB"],"title":"REG-IBA signs contract to install the first proton therapy center in central Italy, in Rome","author":"Globe Newswire","published_at":"2026-09-29T05:00:00.091Z","article_body":"Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA\n(https://www.globenewswire.com/Tracker?data=rcxbww2VrKfpl-przYFETfeBbuTAbxavj5Ignfjm1qBbyKsRAjvHipkW23c4gJDTsrdzOjm51tf7XRy84bpR-g==)\n(Ion Beam Applications S.A., EURONEXT), the world leader in particle\naccelerator technology and the world’s leading provider of proton therapy\nsolutions for the treatment of cancer, today announces it has signed a\ncontract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale\nTumori Regina Elena (IFO), to provide a turnkey proton therapy solution in\nRome, Italy. The center will be the first gantry-based proton therapy system\navailable in central and southern Italy.\n\nFollowing a rigorous public tender process, IBA and its partners Cecchini SRL\nand Gowen SRL, construction companies and RTI (Temporary Grouping of\nCompanies) members, have been selected by IFO to deliver a turnkey compact\ngantry-based Proteus(®)ONE(1) system at the Istituti Fisioterapici\nOspitalieri center in Rome. IFO will use proton therapy treatment modality for\nboth pediatric and adult patients. As proton therapy is not currently\navailable in central or southern Italy, this landmark project will bring the\nlatest and most widely used gantry-based proton therapy technology with proven\nhigh clinical versatility to Italian patients. IFO expects to start treating\npatients in 2030.\n\nThe contract includes the supply of the latest-generation proton therapy\nsystem, Proteus(®)ONE, design, build, installation, and a comprehensive\ntraining & education program as well as a one-year operation and maintenance\nagreement. As the market-leading compact proton therapy solution,\nProteus(®)ONE is designed to continuously evolve and integrate the latest\ntechnological advancements, enabling IBA users to benefit from cutting-edge\ninnovation and adaptable capabilities.\n\nHenri de Romrée, Deputy Chief Executive Officer of IBA, commented: “We are\nproud to partner with IFO on this landmark project, which will make\ngantry-based proton therapy available to patients in central and southern\nItaly for the first time. With Proteus(®)ONE, IBA brings a proven, compact\ngantry solution designed to broaden access to advanced cancer care and support\nthe treatment of a wide range of clinical indications. This collaboration\nreflects our shared commitment to bringing innovative, high-quality cancer\ntreatments closer to patients.”\n\nGiuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO,\nadded: “We are pleased to work with IBA to bring proton therapy closer to\npatients in our region. We are convinced that choosing a gantry-based solution\nwill provide the clinical versatility needed, enabling more patients to\nbenefit from the advantages of proton therapy. This project represents an\nimportant step forward in expanding access to advanced cancer care in central\nand southern Italy.”\n\nThe typical end user price of a Proteus(®️)ONE system with a multiyear\nmaintenance contract ranges between €35 and €45 million.\n\n***ENDS***\n\nAbout IBA\n\nIBA (Ion Beam Applications S.A.) is the world leader in particle accelerator\ntechnology. The company is the leading supplier of equipment and services in\nthe fields of proton therapy, considered one of the most advanced forms of\nradiation therapy available today, as well as industrial sterilization,\nradiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve,\nBelgium, employs approximately 2,300 people worldwide. IBA is a certified B\nCorporation (B Corp) meeting the highest standards of verified social and\nenvironmental performance.\n\nIBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters\nIBAB.BR and Bloomberg IBAB.BB). More information can be found at:\nwww.iba-worldwide.com.\n\nAbout IFO\n\nThe Istituti Fisioterapici Ospitalieri (IFO) of Rome is one of Italy’s\nleading public research hospitals and comprises two Scientific Institutes for\nResearch, Hospitalization and Healthcare (IRCCS): the Regina Elena National\nCancer Institute (IRE), dedicated to oncology, and the San Gallicano\nDermatological Institute (ISG), specialized in dermatology. Founded in 1939,\nIFO combines patient care, clinical research, education, and innovation,\nserving as a national and international reference center for cancer treatment,\ndermatology, translational research, and precision medicine. Located in Rome,\nIFO is accredited by several international organizations and is recognized for\nexcellence in multidisciplinary patient care, advanced therapies, and\nscientific research.\n\nCONTACTS\nThomas Pevenage\nInvestor Relations\n+32 10 475 890\ninvestorrelations@iba-group.com\n\nNathalie van Ypersele\nHead of Communication and Sustainability\n\nDaniel Ernult \nCorporate Communication Manager\n+32 10 475 890\ncommunication@iba-group.com\n\n\n\n(1) Proteus(®)ONE is a brand name of Proteus(®)235\n\n\n\nAttachment\n*     260929-IBA-ProteusONE-Rome-EN\n(https://ml-eu.globenewswire.com/Resource/Download/56163d1f-0181-4ade-900f-f63ce7d332b3)","article_body_html":"","raw_payload":{"data":{"id":"nGNE6vl5ZB-20260929","title":"REG-IBA signs contract to install the first proton therapy center in central Italy, in Rome","author":"Globe Newswire","ticker":"IBAB","created":"2026-09-29T05:00:00.091Z","tickers":["IBAB"],"exchange":"","article_body":"Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA\n(https://www.globenewswire.com/Tracker?data=rcxbww2VrKfpl-przYFETfeBbuTAbxavj5Ignfjm1qBbyKsRAjvHipkW23c4gJDTsrdzOjm51tf7XRy84bpR-g==)\n(Ion Beam Applications S.A., EURONEXT), the world leader in particle\naccelerator technology and the world’s leading provider of proton therapy\nsolutions for the treatment of cancer, today announces it has signed a\ncontract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale\nTumori Regina Elena (IFO), to provide a turnkey proton therapy solution in\nRome, Italy. The center will be the first gantry-based proton therapy system\navailable in central and southern Italy.\n\nFollowing a rigorous public tender process, IBA and its partners Cecchini SRL\nand Gowen SRL, construction companies and RTI (Temporary Grouping of\nCompanies) members, have been selected by IFO to deliver a turnkey compact\ngantry-based Proteus(®)ONE(1) system at the Istituti Fisioterapici\nOspitalieri center in Rome. IFO will use proton therapy treatment modality for\nboth pediatric and adult patients. As proton therapy is not currently\navailable in central or southern Italy, this landmark project will bring the\nlatest and most widely used gantry-based proton therapy technology with proven\nhigh clinical versatility to Italian patients. IFO expects to start treating\npatients in 2030.\n\nThe contract includes the supply of the latest-generation proton therapy\nsystem, Proteus(®)ONE, design, build, installation, and a comprehensive\ntraining & education program as well as a one-year operation and maintenance\nagreement. As the market-leading compact proton therapy solution,\nProteus(®)ONE is designed to continuously evolve and integrate the latest\ntechnological advancements, enabling IBA users to benefit from cutting-edge\ninnovation and adaptable capabilities.\n\nHenri de Romrée, Deputy Chief Executive Officer of IBA, commented: “We are\nproud to partner with IFO on this landmark project, which will make\ngantry-based proton therapy available to patients in central and southern\nItaly for the first time. With Proteus(®)ONE, IBA brings a proven, compact\ngantry solution designed to broaden access to advanced cancer care and support\nthe treatment of a wide range of clinical indications. This collaboration\nreflects our shared commitment to bringing innovative, high-quality cancer\ntreatments closer to patients.”\n\nGiuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO,\nadded: “We are pleased to work with IBA to bring proton therapy closer to\npatients in our region. We are convinced that choosing a gantry-based solution\nwill provide the clinical versatility needed, enabling more patients to\nbenefit from the advantages of proton therapy. This project represents an\nimportant step forward in expanding access to advanced cancer care in central\nand southern Italy.”\n\nThe typical end user price of a Proteus(®️)ONE system with a multiyear\nmaintenance contract ranges between €35 and €45 million.\n\n***ENDS***\n\nAbout IBA\n\nIBA (Ion Beam Applications S.A.) is the world leader in particle accelerator\ntechnology. The company is the leading supplier of equipment and services in\nthe fields of proton therapy, considered one of the most advanced forms of\nradiation therapy available today, as well as industrial sterilization,\nradiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve,\nBelgium, employs approximately 2,300 people worldwide. IBA is a certified B\nCorporation (B Corp) meeting the highest standards of verified social and\nenvironmental performance.\n\nIBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters\nIBAB.BR and Bloomberg IBAB.BB). More information can be found at:\nwww.iba-worldwide.com.\n\nAbout IFO\n\nThe Istituti Fisioterapici Ospitalieri (IFO) of Rome is one of Italy’s\nleading public research hospitals and comprises two Scientific Institutes for\nResearch, Hospitalization and Healthcare (IRCCS): the Regina Elena National\nCancer Institute (IRE), dedicated to oncology, and the San Gallicano\nDermatological Institute (ISG), specialized in dermatology. Founded in 1939,\nIFO combines patient care, clinical research, education, and innovation,\nserving as a national and international reference center for cancer treatment,\ndermatology, translational research, and precision medicine. Located in Rome,\nIFO is accredited by several international organizations and is recognized for\nexcellence in multidisciplinary patient care, advanced therapies, and\nscientific research.\n\nCONTACTS\nThomas Pevenage\nInvestor Relations\n+32 10 475 890\ninvestorrelations@iba-group.com\n\nNathalie van Ypersele\nHead of Communication and Sustainability\n\nDaniel Ernult \nCorporate Communication Manager\n+32 10 475 890\ncommunication@iba-group.com\n\n\n\n(1) Proteus(®)ONE is a brand name of Proteus(®)235\n\n\n\nAttachment\n*     260929-IBA-ProteusONE-Rome-EN\n(https://ml-eu.globenewswire.com/Resource/Download/56163d1f-0181-4ade-900f-f63ce7d332b3)"},"type":"article","timestamp":"2026-09-29T05:00:00.204566384Z","server_sent_at_ms":1790658000204},"received_at":"2026-09-29T05:00:00.274Z","source_url":null},"analysis":{"id":"143492","press_release_id":"154734","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"IBA signed a contract with Rome's IFO to deliver a turnkey gantry-based Proteus ONE proton therapy system, the first in central and southern Italy.\n\nThe win followed a public tender, with IBA partnering with Cecchini SRL and Gowen SRL in a temporary grouping of companies; IFO expects to start treating pediatric and adult patients in 2030.\n\nThe contract covers supply, design, build, installation, training, and a one-year operation and maintenance agreement; typical Proteus ONE system pricing with multiyear maintenance runs €35-€45 million.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"IBA extends its proton therapy leadership with a landmark first-in-region Proteus ONE win in Rome."},"keyFigures":{"dealValueUsd":"€35-€45 million (typical end user price of a Proteus ONE system with multiyear maintenance contract)","customDimensions":{"employees":2300,"patient_treatment_start":"2030"}},"quotedText":"We are proud to partner with IFO on this landmark project, which will make gantry-based proton therapy available to patients in central and southern Italy for the first time.","namedEntities":{"people":[{"name":"Henri de Romrée","role":"Deputy Chief Executive Officer of IBA"},{"name":"Giuseppe Navanteri","role":"Chief Clinical Engineering and Technology officer of IFO"},{"name":"Thomas Pevenage","role":"Investor Relations, IBA"},{"name":"Nathalie van Ypersele","role":"Head of Communication and Sustainability, IBA"},{"name":"Daniel Ernult","role":"Corporate Communication Manager, IBA"}],"products":["Proteus ONE","Proteus 235"],"companies":[{"name":"IBA (Ion Beam Applications S.A.)","ticker":"IBAB","relationship":"filer/contractor"},{"name":"Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO)","relationship":"customer"},{"name":"Cecchini SRL","relationship":"RTI partner"},{"name":"Gowen SRL","relationship":"RTI partner"}],"dollarAmounts":[{"amount":"€35 and €45 million","context":"typical end user price of a Proteus ONE system with multiyear maintenance contract"}]},"materialImpact":{"score":2,"reasoning":"A new turnkey Proteus ONE contract win in Rome, the first gantry-based proton therapy center in central/southern Italy. Meaningful but routine order flow for IBA; typical system value €35-45M, delivery/patient treatment not until 2030."},"tickerRelevance":{"others":[],"primary":"IBAB"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap European listed (EURONEXT)","eventGravity":"contract win, routine order flow","householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"IBA signed a contract with Rome's IFO to deliver a turnkey gantry-based Proteus ONE proton therapy system, the first in central and southern Italy.\n\nThe win followed a public tender, with IBA partnering with Cecchini SRL and Gowen SRL in a temporary grouping of companies; IFO expects to start treating pediatric and adult patients in 2030.\n\nThe contract covers supply, design, build, installation, training, and a one-year operation and maintenance agreement; typical Proteus ONE system pricing with multiyear maintenance runs €35-€45 million.","key_figures":{"dealValueUsd":"€35-€45 million (typical end user price of a Proteus ONE system with multiyear maintenance contract)","customDimensions":{"employees":2300,"patient_treatment_start":"2030"}},"named_entities":{"people":[{"name":"Henri de Romrée","role":"Deputy Chief Executive Officer of IBA"},{"name":"Giuseppe Navanteri","role":"Chief Clinical Engineering and Technology officer of IFO"},{"name":"Thomas Pevenage","role":"Investor Relations, IBA"},{"name":"Nathalie van Ypersele","role":"Head of Communication and Sustainability, IBA"},{"name":"Daniel Ernult","role":"Corporate Communication Manager, IBA"}],"products":["Proteus ONE","Proteus 235"],"companies":[{"name":"IBA (Ion Beam Applications S.A.)","ticker":"IBAB","relationship":"filer/contractor"},{"name":"Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO)","relationship":"customer"},{"name":"Cecchini SRL","relationship":"RTI partner"},{"name":"Gowen SRL","relationship":"RTI partner"}],"dollarAmounts":[{"amount":"€35 and €45 million","context":"typical end user price of a Proteus ONE system with multiyear maintenance contract"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T05:00:08.022Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap European listed (EURONEXT)","eventGravity":"contract win, routine order flow","householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":7735,"modelName":"glm-5.3-flashx"}}